BioSpace News Archive

One-year data from a Phase II study of Newron’s schizophrenia candidate evenamide showed sustained efficacy and continued improvements in symptoms of psychosis and disease severity.

Pfizer and Valneva are dropping approximately half of enrolled participants in the Phase III VALOR study for their Lyme disease vaccine candidate, VLA15.

Moderna announced mixed interim results Thursday from a Phase III trial of mRNA seasonal flu vaccine candidate, mRNA-1010.

If Leqembi is granted priority review from the agency, full approval could come as soon as July, Ivan Cheung, chairman and CEO, Eisai Inc., told CNBC Thursday.

Abivax SA announced the appointment of Dr. Sheldon Sloan, M.D., M. Bioethics, as new Chief Medical Officer, effective on March 1, 2023.

REGENXBIO Inc. announced that three oral and eight poster presentations will be presented at the 19th Annual WORLDSymposium™ 2023, taking place in Orlando, Florida from February 22 through 26, 2023.

Daxor Corporation, the global leader in blood volume measurement technology, announces the appointment of Linda Cooper as Vice President of Project Management.

Jasper Therapeutics, Inc. announced new positive Phase 1 data on briquilimab in combination with fludarabine and low-dose irradiation conditioning in older adults with acute myeloid leukemia or myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplant.

AtriCure, Inc., a leading innovator in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, announced that the company will be participating in the upcoming Oppenheimer 33rd Annual Healthcare Conference.

SciSparc Ltd. announced that its MitoCareX Bio Ltd. joint venture, which focuses on the discovery and development of potential drugs for cancer, rare diseases and other life-threatening conditions, has achieved its first milestone pursuant to the March 10, 2022 Founders and Investment Agreement with respect to MitoCare X Bio.